Clinical-Grade Testing Delivered to Your Doorstep

Today more than ever, you have access to a wealth of health information. But often, what’s missing is a reliable, accurate way to understand your health on a deeper level and use that information to make more informed decisions about you treatment plans.

Better To Know’s at-home genetic testing kits are easy to use and provide medically actionable insights that can help you plan for a better, healthier future.

Better To Know Test Kit

Our process is quick and easy. In just three simple steps, you can initiate the order and get your results:


Choose your test and place your order. You’ll receive your kit in about 2 business days after your order is placed.



Activate your kit online using your identification code. This unique code will ensure your test results are linked to you and remain confidential.



Follow the kit instructions for the sample collection and send it back to us

Its that easy!
Within 48-72 hours, you’ll be notified via email that your test results are ready to view. You can view them on our secure web portal and share them with your physician.

COVID-19 Test Kit
Better To Know Test Kit

Important Information

The test uses the reverse transcription polymerase chain reaction (RT-PCR) testing method.

The test can only be ordered by a medical professional. When an order is placed, a healthcare provider in the state of the patient will review the order and the patient’s details and order the test. Healthcare providers across the entire U.S. can send patient samples to Better To Know for processing.

Better To Know does not provide medical advice and patients seeking advice should contact their healthcare provider. If you think you have been exposed to COVID 19 and develop a fever and symptoms, such as cough or difficulty breathing, call your healthcare provider.

Emergency Use Authorization

The Better To Know Test has not been FDA cleared or approved. It has been authorized by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests. The test has been authorized only for the detection of RNA from SARS-CoV-2 virus and diagnosis of SARS-CoV-2 virus infection, not for any other viruses or pathogens. It is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection of SARS-CoV-2 virus under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorization is terminated or revoked sooner.